- Home
- AIZ vs INCY Comparison
AIZ vs INCY Comparison
Compare AIZ & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIZ
- INCY
- Stock Information
- Founded
- AIZ 1892
- INCY 1991
- Country
- AIZ United States
- INCY United States
- Employees
- AIZ N/A
- INCY N/A
- Industry
- AIZ Property-Casualty Insurers
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- AIZ Finance
- INCY Health Care
- Exchange
- AIZ Nasdaq
- INCY Nasdaq
- Market Cap
- AIZ 10.9B
- INCY 13.0B
- IPO Year
- AIZ N/A
- INCY 1993
- Fundamental
- Price
- AIZ $211.15
- INCY $86.64
- Analyst Decision
- AIZ Strong Buy
- INCY Buy
- Analyst Count
- AIZ 7
- INCY 20
- Target Price
- AIZ $235.57
- INCY $80.31
- AVG Volume (30 Days)
- AIZ 438.6K
- INCY 1.8M
- Earning Date
- AIZ 11-04-2025
- INCY 10-28-2025
- Dividend Yield
- AIZ 1.52%
- INCY N/A
- EPS Growth
- AIZ N/A
- INCY 900.04
- EPS
- AIZ 13.78
- INCY 4.37
- Revenue
- AIZ $12,304,900,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- AIZ $7.85
- INCY $16.26
- Revenue Next Year
- AIZ $4.82
- INCY $11.07
- P/E Ratio
- AIZ $15.33
- INCY $19.83
- Revenue Growth
- AIZ 6.42
- INCY 18.87
- 52 Week Low
- AIZ $174.97
- INCY $53.56
- 52 Week High
- AIZ $230.55
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- AIZ 53.65
- INCY 64.89
- Support Level
- AIZ $212.33
- INCY $83.41
- Resistance Level
- AIZ $220.54
- INCY $87.99
- Average True Range (ATR)
- AIZ 3.31
- INCY 1.68
- MACD
- AIZ -0.82
- INCY -0.37
- Stochastic Oscillator
- AIZ 24.38
- INCY 70.52
About AIZ Assurant Inc.
Assurant Inc is a protection company that partners with the brands to safeguard and service connected devices, homes and automobiles. It operate in North America, Latin America, Europe and Asia Pacific through two operating segments: Global Lifestyle and Global Housing. Global Lifestyle: includes mobile device solutions (including extended service contracts, insurance policies and related services), extended service contracts and related services for consumer electronics and appliances, and financial services and other insurance products. Global Housing: includes lender-placed homeowners, manufactured housing and flood insurance, as well as voluntary manufactured housing, condominium and homeowners insurance. Key revenue is generated from Global Lifestyle segment.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.